240 related articles for article (PubMed ID: 33713038)
1. Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation.
Hawash M; Kahraman DC; Cetin-Atalay R; Baytas SN
Chem Biodivers; 2021 May; 18(5):e2001037. PubMed ID: 33713038
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Fan X; Deng J; Shi T; Wen H; Li J; Liang Z; Lei F; Liu D; Zhang H; Liang Y; Hao X; Wang Z
Bioorg Chem; 2021 Sep; 114():105154. PubMed ID: 34378540
[TBL] [Abstract][Full Text] [Related]
4. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach.
Preti D; Romagnoli R; Rondanin R; Cacciari B; Hamel E; Balzarini J; Liekens S; Schols D; Estévez-Sarmiento F; Quintana J; Estévez F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1225-1238. PubMed ID: 30141353
[TBL] [Abstract][Full Text] [Related]
7. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
Harras MF; Sabour R
Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
[TBL] [Abstract][Full Text] [Related]
10. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis.
Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC
Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935
[TBL] [Abstract][Full Text] [Related]
11. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
12. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
13. The cytotoxic and mechanistic effects of aaptamine on hepatocellular carcinoma.
Li QL; Zhang PP; Wang PQ; Yu HB; Sun F; Hu WZ; Wu WH; Zhang X; Chen F; Chu ZY; Zhang JP; Chen SS; Lin HW
Anticancer Agents Med Chem; 2015; 15(3):291-7. PubMed ID: 25403168
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
16. MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest.
Wilson JM; Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
J Surg Res; 2014 Oct; 191(2):280-5. PubMed ID: 24996256
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel diflunisal hydrazide-hydrazones as anti-hepatitis C virus agents and hepatocellular carcinoma inhibitors.
Şenkardeş S; Kaushik-Basu N; Durmaz İ; Manvar D; Basu A; Atalay R; Küçükgüzel ŞG
Eur J Med Chem; 2016 Jan; 108():301-308. PubMed ID: 26695731
[TBL] [Abstract][Full Text] [Related]
18. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells.
Wang CJ; Guo X; Zhai RQ; Sun C; Xiao G; Chen J; Wei MY; Shao CL; Gu Y
Eur J Med Chem; 2021 Nov; 224():113671. PubMed ID: 34237623
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
Omar HA; Zaher DM; Srinivasulu V; Hersi F; Tarazi H; Al-Tel TH
Eur J Med Chem; 2017 Oct; 139():804-814. PubMed ID: 28865276
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Hawash MM; Kahraman DC; Eren F; Cetin Atalay R; Baytas SN
Eur J Med Chem; 2017 Mar; 129():12-26. PubMed ID: 28219046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
